Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use

(2013) Mette Charlot   ANNALS OF INTERNAL MEDICINE

Proton Pump Inhibitor Therapy Associated with Lower Glycosylated Hemoglobin Levels in Type 2 Diabetes

(2012) M. A. Crouch et al.   Journal of the American Board of Family Medicine

Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides

(2011) J. F. Rehfeld   Acta Physiologica

Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD

(2011) Jean-Paul Galmiche et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis

(2010) Karin D. Hove et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes

(2010) T. B. Bödvarsdóttir et al.   DIABETOLOGIA

Comparison of Outcomes Twelve Years After Antireflux Surgery or Omeprazole Maintenance Therapy for Reflux Esophagitis

(2009) Lars Lundell et al.   Clinical Gastroenterology and Hepatology

Proton pump inhibitors as a treatment method for type II diabetes

(2009) Ivan N. Mefford et al.   MEDICAL HYPOTHESES

Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes

(2008) Søren S Lund et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The art of measuring gastrin in plasma: A dwindling diagnostic discipline?

(2008) Jens F. Rehfeld   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION